Research Signal – Source date 2021-03-01
For people with cancer, the pandemic raised a difficult question: could a treatment that changes immune activity also make COVID-19 more dangerous? In March 2021, an editorial perspective in the Journal for ImmunoTherapy of Cancer introduced a review series meant to help address that question. Its authors described emerging evidence suggesting checkpoint inhibitors might not worsen outcomes for patients with both cancer and COVID-19, while stressing that the risks of continuing immunotherapy still needed careful study.
The perspective also pointed to an unexpected connection. Some of the research experience and trial methods developed in immuno-oncology were relevant to the response against the new coronavirus. That shared research history offered useful context, but it did not make cancer treatment and COVID-19 interchangeable problems.
Why treatment effects were hard to separate
A patient’s COVID-19 outcome can reflect several things at once. Cancer itself may affect vulnerability to infection, while an immune-modulating treatment may also influence how the body responds. When both are present, an observed outcome cannot automatically be attributed to the treatment alone. The authors identified this entanglement as a central challenge for understanding COVID-19 in people with cancer.
They highlighted checkpoint inhibitors as one important question. These drugs release brakes on immune cells so they can attack cancer. Emerging data available to the authors suggested that checkpoint inhibitors might not predispose people with cancer and COVID-19 to worse outcomes. That was a tentative reading of early evidence, not a patient-specific safety guarantee or a measure of the drug’s independent effect. Clinicians still needed better evidence to weigh the possible benefits of cancer treatment against risks during the pandemic.
The article also mentioned an isolated report of a person with lymphoma whose cancer went into complete remission after SARS-CoV-2 infection, without an intervention. The authors used it to illustrate how complicated the relationship between infection, immunity and cancer could be. A single case cannot show that infection treats cancer or establish what would happen to other patients.
Similar inflammation, different clinical problems
Severe COVID-19 can involve dysregulated inflammation. The perspective compared this with cytokine release syndrome, an intense inflammatory reaction associated with engineered T-cell therapy, including CAR T-cell treatment. Both conditions involve elevated inflammatory signals, but the authors cautioned that the resemblance did not make them the same disease.
That matters because the immune system has different jobs across the course of illness. A response that helps protect against a virus is not the same as inflammation that becomes damaging in severe disease. The authors argued that researchers would need to distinguish protective immunity from excessive inflammation and understand how these processes interact with cancer immunotherapies. They expected management approaches for severe COVID-19 and cytokine release syndrome to diverge; the perspective did not establish that the conditions should receive the same treatment.
A research field with tools to contribute
Immuno-oncology had faced major obstacles in maintaining essential cancer care during the outbreak. At the same time, the field brought experience that could contribute to pandemic research. mRNA vaccines, which were producing protection rates of up to 95% against SARS-CoV-2 infection in published trials cited by the authors, had also been investigated for decades as potential tumor immunotherapies. That history connected the research fields; the COVID-19 trial results did not demonstrate that an mRNA cancer vaccine works.
The authors also pointed to adaptive trial design, a strength of oncology research. When a disease presents in varied ways and the standard of care changes quickly, trials need to adapt while still preserving the ability to assess whether an intervention helps. The perspective described that experience as useful to studies of COVID-19 interventions. It did not claim that any particular treatment had succeeded because of those methods.
The publication’s role was to introduce an invited series of reviews, not to report a new patient study. The planned reviews would cover immune responses to SARS-CoV-2, immune-based therapies, and populations affected by both cancer and COVID-19. Topics included checkpoint inhibitors across several cancers, lung cancer, and antibody-based antiviral therapies. These were subjects the series intended to examine, not findings established by this introductory perspective.
How clearer COVID-19 risks could protect cancer care
Better evidence that separates risks linked to cancer from those linked to a treatment—and distinguishes protective immunity from severe inflammation—could help clinicians make more informed decisions about preserving needed immunotherapy during infectious outbreaks. It could also support more precise choices about immune interventions as a disease changes over time. That capability depends on stronger patient-outcome and treatment evidence than this March 2021 perspective provided.
Key Sources
- Primary source: Perspectives on COVID-19 and cancer immunotherapy: a review series.
DOI or Journal Page · Review or Meta-Analysis · 2021-03-01
Keep exploring